Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Monday, June 30, 2025 1 min read
Key Takeaway: AbbVie Inc. has updated its guidance for adjusted diluted earnings per share (EPS) for the quarters and full year ended June 30 and December 31, 2025. The updated guidance includes the impact of acquired IPR D and milestones expenses, projecting adjusted diluted EPS to range between $2.84 and $2.88 for Q2 2025. For the full year 2025, adjusted diluted EPS is expected to range from $11.67 to $11.87, excluding any additional impacts from future expense forecasts.
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie has provided updated guidance for adjusted diluted EPS.
The company is projecting future expense impacts transparently.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended June 30, 2025
Full-Year Ended December 31, 2025
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q2 2025 acquired IPR D and milestones expense
$
-
$
3.26
$
3.30
$
248
$
12.09
$
12.29
Q2 2025 acquired IPR D and milestones expense
823
(0.42)
(0.42)
823
(0.42)
(0.42)
Guidance including Q2 2025 acquired IPR D and milestones expense a
$
823
$
2.84
$
2.88
$
1,071
$
11.67
$
11.87
a The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the second quarter of 2025, as both cannot be reliably forecasted.
Frequently Asked Questions
What is the Q2 2025 acquired IPR D and milestones expense?
The Q2 2025 acquired IPR D and milestones expense is $823 million.
How does acquired IPR D affect adjusted diluted EPS?
Acquired IPR D results in an adjusted diluted EPS decrease of $0.42.
What is the adjusted diluted EPS range for 2025?
The 2025 adjusted diluted EPS range is $11.67 to $11.87.
Is the guidance affected by future IPR D expenses?
No, guidance excludes future IPR D and milestone expenses beyond Q2 2025.
What was the previous adjusted EPS before Q2 2025 expenses?
The previous adjusted EPS guidance was between $3.26 and $3.30.